CN-121971583-A - Application of dipeptide in preparation of medicine for treating and/or preventing osteoporosis

Abstract

The application discloses application of dipeptide in preparation of a medicament for treating and/or preventing osteoporosis, and relates to the technical field of peptide-containing pharmaceutical preparations. The application of the dipeptide in preparing the medicament for treating and/or preventing the osteoporosis, wherein the dipeptide comprises histidine-leucine, is harmless to human bodies, has no obvious adverse reaction after long-term use, can be applied to preparing the medicament for treating and/or preventing the osteoporosis, and provides a safe and effective novel method for treating and/or preventing the osteoporosis.

Inventors

• LI PENG
• LI JIANHAO
• LIN HAO
• LIU YUANYUAN

Assignees

• 广东医科大学附属医院

Dates

Publication Date

20260505

Application Date

20260123

Claims (10)

1. 1. Use of a dipeptide for the manufacture of a medicament for the treatment and/or prevention of osteoporosis, characterized in that the dipeptide is histidine-leucine.
2. 2. The use according to claim 1, wherein the osteoporosis comprises at least one of postmenopausal osteoporosis, senile osteoporosis, glucocorticoid-induced osteoporosis, disuse osteoporosis, osteoporosis secondary to other diseases.
3. 3. The use according to claim 1, wherein the dipeptide promotes bone marrow mesenchymal stem cells to osteoblast differentiation.
4. 4. The use of claim 1, wherein the dipeptide induces up-regulated expression of a marker protein for osteogenic differentiation.
5. 5. The use of claim 1, wherein the dipeptide mitigates a decrease in at least one of bone mineral density, bone volume percentage of femur, number of bone trabeculae.
6. 6. A pharmaceutical composition for the treatment and/or prophylaxis of osteoporosis comprising a dipeptide or a pharmaceutically acceptable salt thereof; The dipeptide is histidine-leucine.
7. 7. The pharmaceutical composition for treating and/or preventing osteoporosis of claim 6, wherein said osteoporosis comprises at least one of postmenopausal osteoporosis, senile osteoporosis, glucocorticoid-like osteoporosis, disuse osteoporosis, osteoporosis secondary to other diseases.
8. 8. The pharmaceutical composition for treating and/or preventing osteoporosis of claim 6, wherein said dipeptide promotes osteogenic differentiation of bone marrow mesenchymal stem cells into osteoblasts.
9. 9. The pharmaceutical composition for treating and/or preventing osteoporosis of claim 6, wherein said dipeptide induces up-regulated expression of a marker protein for osteogenic differentiation.
10. 10. The pharmaceutical composition for treating and/or preventing osteoporosis of claim 6, wherein said dipeptide mitigates a decrease in at least one of bone mineral density, bone volume percentage of femur, number of bone trabeculae.

Description

Application of dipeptide in preparation of medicine for treating and/or preventing osteoporosis Technical Field The application relates to the technical field of peptide-containing pharmaceutical preparations, in particular to application of dipeptide in preparation of a medicament for treating and/or preventing osteoporosis. Background The existing main clinical therapies of osteoporosis such as bisphosphonates, estrogen modulators and the like can partially improve bone density, and have obvious adverse reactions after long-term use. Therefore, searching for new safe and effective therapeutic means becomes a key to be solved in the field of osteoporosis research. Disclosure of Invention The main purpose of the application is to provide an application of dipeptide in preparing a medicament for treating and/or preventing osteoporosis, aiming at solving the problem that the conventional medicament for treating and/or preventing osteoporosis has obvious adverse reaction after long-term use. To achieve the above object, in a first aspect, the present application proposes the use of a dipeptide, which is histidine-leucine, for the manufacture of a medicament for the treatment and/or prevention of osteoporosis. In some embodiments, the osteoporosis comprises at least one of postmenopausal osteoporosis, senile osteoporosis, glucocorticoid-induced osteoporosis, disuse osteoporosis, osteoporosis secondary to other diseases. In some embodiments, the dipeptide promotes bone marrow mesenchymal stem cells to osteoblast differentiation into bone cells. In some embodiments, the dipeptide induces up-regulated expression of a marker protein of osteogenic differentiation. In some embodiments, the dipeptide mitigates a decrease in at least one of bone mineral density, bone volume percentage of the femur, number of bone trabeculae. In a second aspect, the present application also provides a pharmaceutical composition for the treatment and/or prevention of osteoporosis, comprising a dipeptide or a pharmaceutically acceptable salt thereof; The dipeptide is histidine-leucine. In some embodiments, the osteoporosis comprises at least one of postmenopausal osteoporosis, senile osteoporosis, glucocorticoid-induced osteoporosis, disuse osteoporosis, osteoporosis secondary to other diseases. In some embodiments, the dipeptide promotes bone marrow mesenchymal stem cells to osteoblast differentiation into bone cells. In some embodiments, the dipeptide induces up-regulated expression of a marker protein of osteogenic differentiation. In some embodiments, the dipeptide mitigates a decrease in at least one of bone mineral density, bone volume percentage of the femur, number of bone trabeculae. The application provides application of dipeptide in preparing a medicament for treating and/or preventing osteoporosis, wherein the dipeptide comprises histidine-leucine, is harmless to human body, has no obvious adverse reaction after long-term use, has the effects of promoting bone mesenchymal stem cells to be osteogenic differentiated into bone cells, inducing up-regulated expression of marker proteins of osteogenic differentiation, relieving reduction of at least one of bone mineral density, bone volume percentage of femur and bone trabecular number, and can be further applied to preparing the medicament for treating and/or preventing osteoporosis, thereby providing a safe and effective novel method for treating and/or preventing osteoporosis. The foregoing description is only an overview of the present invention, and is intended to be implemented in accordance with the teachings of the present invention in order that the technical means thereof may be more clearly understood, and in order that the above-mentioned and other objects, features and advantages of the present invention may be more readily understood, the following detailed description of the present invention. Drawings In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings that are required in the embodiments or the description of the prior art will be briefly described, and it is obvious that the drawings in the following description are only some embodiments of the present application, and other drawings may be obtained according to the structures shown in these drawings without inventive effort for a person skilled in the art. FIG. 1 is a chart showing alkaline phosphatase staining of hBMSCs induced by His-Leu at different concentrations according to the examples of the present application; FIG. 2 is a chart showing alizarin red staining of different concentrations of His-Leu induced osteogenic differentiation of hBMSCs provided in the examples of the present application; FIG. 3 shows gel electrophoresis of marker proteins for inducing osteogenic differentiation of hBMSCs by His-Leu provided by the embodiment of the application; Fig. 4 is a graph showing the change of the bone mass of femur of differ